Celgene Corporation

Celgene Corporation

CELG - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$129.66B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Celgene CorporationCelgene Corporation143.97%39%-1.9

Earnings Call Q3 2026

October 29, 2026 - AI Summary

Q3 headline performance & growth (good) - Total revenue +7% YoY to ~$13.1B (non-GAAP basis per call). - Growth portfolio revenue +12% to ~$7.7B, helped by broad differentiation across the portfolio. - Key brands highlighted: Reblozyl +22% (~$750M), Breyanzi +48% (~$526M), Eliquis +26% (~$4.7B), Camzyos +42% (~$420M), Opdualag continued strong growth, and Cobenfy +33% to ~$57M (with note of destocking vs prescriptions in the quarter).
Major pipeline/clinical & regulatory momentum (good, and somewhat surprising in volume) - CEO emphasized “derisking the pipeline” after multiple positive registrational readouts/approvals in recent months. - Symvexis: FDA accelerated approval as the first approved CELMoD for multiple myeloma (newest portfolio addition). - Company encouraged by Phase 3 PFS improvement; data to be presented at ASH in December. - Mezigdomide: PDUFA 05/13/2027 (potential next oral CELMoD option). - Admilparant (IPF): Phase 3 HARMONi-6 met its primary endpoint at 60 mg; 100 mg showed improvement but not statistically significant (important nuance/possible concern). - RAISE 101 (GEP-NET alpha RPT) interim Phase 3 readouts: PFS improvement vs post–lutetium therapy, with FDA discussions on next steps. - Arlocell (GPRC5D CAR T): Phase 2 registrational data positive; positioned for potential standard-of-care in post-BCMA quadruple-exposed myeloma.
Commercial execution: early launch feedback & what to expect next (opportunity + some near-term variability) - Symvexis launch (first weeks): early adoption positive; feedback driven by MRD results and simplicity of oral use; uptake expected to come primarily from community (~70–80% of patients). - Camzyos Q3 growth affected by typical inventory drawdown; expected normalization in Q4 (near-term sales pattern risk/volatility to watch). - Cobenfy: sequential destocking offset increased demand; company expects revenue to track prescription volume more closely going forward (implies prior quarter effects were partly inventory-related).

Exclusive for Stockcircle Pro members

Sign upSign Up

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$129.66 Billion
Enterprise Value$164.89 Billion
Dividend yield3.97%
Earnings per Share$5.51
Beta1.34
Outstanding Shares706,200,000

Return

Return on Equity39.49%ROE
Return on Assets10.41%
Return on Invested Capital14.61%

Valuation & Multiples

P/E Ratio14.03P/E Ratio
PEG-791.98PEG
Price to Sales0.0Price to Sales
Price to Book Ratio0.0Price to Book Ratio
Enterprise Value to Revenue3.3
Enterprise Value to EBIT16.12
Enterprise Value to Net Income17
Total Debt to Enterprise0.27
Debt to Equity1.91Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Bristol-Myers Squibb Company Ce

34,100 employees
CEO: Christopher S. Boerner

Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse p...